Literature DB >> 23773369

Drug-eluting stents versus bare-metal stents in patients with decreased GFR: a meta-analysis.

Zhi Jian Wang1, Kishore J Harjai, Chetan Shenoy, Fei Gao, Dong Mei Shi, Yu Yang Liu, Ying Xin Zhao, Yu Jie Zhou.   

Abstract

BACKGROUND: Decreased estimated glomerular filtration rate (eGFR) is a strong predictor of both mortality and subsequent cardiac events after percutaneous coronary intervention. The safety and efficacy of drug-eluting (DESs) versus bare-metal stents (BMSs) in this population have not been evaluated adequately. STUDY
DESIGN: A systematic review and meta-analysis. SETTING &amp; POPULATION: Studies involving the comparison of clinical outcomes between DESs and BMSs in patients with eGFR <60 mL/min/1.73 m(2). Studies exclusively involving patients with ST-segment elevation myocardial infarction were excluded. SELECTION CRITERIA FOR STUDIES: MEDLINE (on Ovid), EMBASE, and the Cochrane Library databases from 2002-2013 were searched for studies comparing DESs with BMSs in patients with eGFR <60 mL/min/1.73 m(2). INTERVENTION: DES versus BMS implantation. OUTCOMES: Mortality, repeat revascularization, myocardial infarction, and stent thrombosis.
RESULTS: Data from 26 comparative studies with 66,840 patients were included. Compared with BMSs, DESs were associated with significant reductions in repeat revascularization (OR, 0.61; 95% CI, 0.50-0.74; P < 0.001) and myocardial infarction (OR, 0.85; 95% CI, 0.79-0.92; P < 0.001), with no detectable difference in stent thrombosis (OR, 0.72; 95% CI, 0.46-1.12; P = 0.1). The superiority of DESs over BMSs in decreasing mortality also was documented (OR, 0.77; 95% CI, 0.65-0.90; P = 0.01). This survival benefit of DESs over BMSs was attenuated in randomized controlled trials or adjusted observational studies versus unadjusted observational studies. LIMITATIONS: Most studies were observational studies. Meta-analysis was not performed on individual patient data.
CONCLUSIONS: DES use in patients with eGFR <60 mL/min/1.73 m(2) is associated with a reduced rate of repeat revascularization and myocardial infarction without increased risk of stent thrombosis. The true effect of DESs versus BMSs on mortality needs to be confirmed by randomized controlled trials.
Copyright © 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Kidney; coronary disease; meta-analysis; stents

Mesh:

Year:  2013        PMID: 23773369     DOI: 10.1053/j.ajkd.2013.04.014

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

1.  The Impact of Admission Serum Creatinine Derived Estimated Glomerular Filtration Rate on Major Adverse Cardiac Events in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Mahmut Uluganyan; Gurkan Karaca; Turker Kemal Ulutas; Ahmet Ekmekci; Eyup Tusun; Ahmet Murat; Bayram Koroglu; Huseyin Uyarel; Nijad Bakhshaliyev; Mehmet Eren
Journal:  J Clin Med Res       Date:  2016-02-27

Review 2.  Comparison of Drug-Eluting and Bare Metal Stents in Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis.

Authors:  Renjie Lu; Fenglei Tang; Yan Zhang; Xishan Zhu; Shanmei Zhu; Ganlin Wang; Yinfeng Jiang; Zhengda Fan
Journal:  J Am Heart Assoc       Date:  2016-11-07       Impact factor: 5.501

3.  Meta-analysis of studies using statins as a reducer for primary liver cancer risk.

Authors:  Guo-Chao Zhong; Yan Liu; Yuan-Yuan Ye; Fa-Bao Hao; Kang Wang; Jian-Ping Gong
Journal:  Sci Rep       Date:  2016-05-20       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.